International staging system for multiple myeloma.
By P. Greipp, J. Miguel, B. Durie, J. Crowley, B. Barlogie, J. Bladé, M. Boccadoro, J. Child, H. Avet-Loiseau, R. Kyle and 10 more. Journal of Clinical Oncology, 2005
2,601 citations recorded by the source corpus.
Subfields: Hematology, Oncology
View Paper: https://www.semanticscholar.org/paper/8967317de4ee15401f53110239412c0cc8741436
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hematology
In Oncology
Citations in the corpus
- Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. (2008, neutral): “Median age, y (range) 57 (17-86) — Younger than 60 y 186 (62) 140 (75) 60 to 69 y 73 (24) 56 (77) 70 y or older 41 (14) 21 (51) Male 211 (70) 154 (73) Female 89 (30) 63 (71) Median time from diagnosis, mo (range) 24 (0-155) — Rai stage 0 11 (4) 10 (91) Rai stages I to II 182 (61) 136 (75) Rai stages”
- Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. (2012, background): “2-microglobulin is an important prognostic factor in myeloma, part of the International Staging System, and often considered a surrogate marker of tumor burden.(30) In the current study, we explored additional plasma cell–related characteristics to determine if these would allow us to explain some o”
- Revised International Staging System for Multiple Myeloma: a report from IMWG (2015, neutral): “No other risk factors 863 (74) 763 (65) 406 (57) Plus high-risk CA 200 (17) 262 (22) 159 (22) Plus high LDH level 84 (7) 114 (10) 107 (15) Plus high-risk CA and high LDH level 24 (2) 35 (3) 43 (6)”
- Multiple myeloma: 2022 update on diagnosis, risk stratification, and management (2022, methodology): “burden in multiple myeloma has traditionally been assessed using the Durie–Salmon staging (DSS)(50) and the International Staging System (ISS).(51,52) Disease biology is best reflected based on the molecular subtype of multiple myeloma (Table 2), the presence or absence of secondary cytogenetic abno”
- International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders (2009, background): “(Kyrtsonis MC et al.(32) Prognostic value of serum-free light chain ratio at diagnosis in multiple myeloma.”